Fidaxomicin cures C.diff infections like vancomycin; prevents more recurrences (RCT, NEJM) - PulmCCM
Advertisement
Feb 122011
 

Louie et al report results of a phase 3 industry-funded trial of fidaxomicin, a poorly absorbed oral macrolide that’s bacteriocidal vs C. difficile. The new drug was equivalent to oral vanco in curing C.diff infections (~90%), and superior at preventing recurrences (~14% vs 24%). It did not prevent recurrences of the more lethal and increasingly prevalent NAP1/BI/027 strain of C.diff. (n=629) NEJM 2011;364:422-431.

Liked this post? Get a weekly email update (no spam, ever), and explore our library of pulmonary and critical care guidelines, practice updates and review articles.

PulmCCM is an independent publication, not affiliated with or endorsed by any other organization, society and/or journal referenced on the website.

Leave a Comment